1 JAPANESE IMPERIAL COUPLE ATTEND WELCOME CEREMONY IN MONGOLIA WWW.ENGLISH.KYODONEWS.NET  PUBLISHED:2025/07/08      2 CU MONGOLIA EXPANDS LOGISTICS HUB TOWARD 1,000-STORE GOAL WWW.KOREAHERALD.COM PUBLISHED:2025/07/08      3 KHAAN QUEST DEMONSTRATES ‘STRENGTH AND RESOLVE’ OF PARTNERS TO SEEK PEACE WWW.IPDEFENSEFORUM.COM PUBLISHED:2025/07/08      4 EUROPEAN BANK FOR RECONSTRUCTION AND DEVELOPMENT TO INCREASE INVESTMENTS WWW.MONTSAME.MN PUBLISHED:2025/07/08      5 UCHRAL NYAM-OSOR: ECONOMIC IMMUNITY MUST BE OUTCOME OF LONG-TERM INTELLIGENT POLICY WWW.MONTSAME.MN PUBLISHED:2025/07/08      6 MONGOLIA HOSTS ASIA-PACIFIC AIR TRANSPORT FACILITATION FORUM WWW.MONTSAME.MN PUBLISHED:2025/07/08      7 TMK ENERGY SIGNS DRILLING CONTRACT FOR LF-07 PRODUCTION WELL IN MONGOLIA WWW.TIPRANKS.COM PUBLISHED:2025/07/08      8 JAPAN EMPEROR, EMPRESS ARRIVE IN MONGOLIA WWW.NIPPON.COM PUBLISHED:2025/07/07      9 KFAED SUPPORTS MONGOLIA AIRPORT EXPANSION WWW.KUWAITTIMES.COM PUBLISHED:2025/07/07      10 DIPLOMATIC TIES ESTABLISHED WITH ALL UN MEMBER STATES WWW.UBPOST.MN PUBLISHED:2025/07/07      МОНГОЛ УЛСЫН ЕРӨНХИЙЛӨГЧ У.ХҮРЭЛСҮХ, ГЭРГИЙ Л.БОЛОРЦЭЦЭГ БОЛОН ЯПОН УЛСЫН ЦОГ ЖАВХЛАНТ ЭЗЭН ХААН НАРҮХИТО, ЭРХЭМ ДЭЭД ХАТАН МАСАКО НАР АЛБАН ЁСНЫ УУЛЗАЛТ ХИЙЛЭЭ WWW.MONTSAME.MN НИЙТЭЛСЭН:2025/07/08     Г.ЗАНДАНШАТАР: ХӨРӨНГӨ ОРУУЛАГЧАА УРЬЧИХААД УРДАГГҮЙ, ЗАЛЧИХААД ЗААМДДАГГҮЙ УЛС БАЙХ ЁСТОЙ WWW.ZINDAA.MN НИЙТЭЛСЭН:2025/07/08     Н.УЧРАЛ: ҮҮСМЭЛ ОРДУУДЫН 50+1 ХУВИЙГ ТӨР, АРД ТҮМНИЙ ЭЗЭМШИЛД АВАХ ЗАРЧМЫГ БАРИМТАЛНА WWW.ITOIM.MN НИЙТЭЛСЭН:2025/07/08     Г.ЗАНДАНШАТАРЫН ТЭРГҮҮЛСЭН ЗАСГИЙН ГАЗАР БАРИМТАЛЖ АЖИЛЛАХ БОДЛОГОО ТАНИЛЦУУЛЛАА WWW.ITOIM.MN НИЙТЭЛСЭН:2025/07/08     “МОНГОЛЫН ЭДИЙН ЗАСГИЙН ФОРУМ-2025”: ТӨР БОДЛОГО, ЧИГЛЭЛЭЭ ТОДОРХОЙ БАЙЛГАХЫГ ХУВИЙН ХЭВШЛҮҮД ИЛЭРХИЙЛЭВ WWW.EGUUR.MN НИЙТЭЛСЭН:2025/07/08     МОНГОЛЫГ СААРАЛ ЖАГСААЛТАД ОРУУЛЖ МЭДЭХ 7.3 ИХ НАЯДЫН АСУУДЛААР Д.ЗАГДЖАВ БИШ ЯАГААД С.МАГНАЙСҮРЭН АМ НЭЭВ WWW.EGUUR.MN НИЙТЭЛСЭН:2025/07/08     ЗАСГИЙН ГАЗАР НЭН ТЭРГҮҮНД ЯМАР АЖИЛ ХИЙХ ЁСТОЙ ТАЛААР ИРГЭДЭЭС САНАЛ АВЧ ЭХЭЛЛЭЭ WWW.NEWS.MN НИЙТЭЛСЭН:2025/07/08     ЯПОН УЛСЫН ЦОГ ЖАВХЛАНТ ЭЗЭН ХААН НАРҮХИТО, ЭРХЭМ ДЭЭД ХАТАН МАСАКО НАР МОНГОЛ УЛСАД ТӨРИЙН АЙЛЧЛАЛ ХИЙХЭЭР ХҮРЭЛЦЭН ИРЛЭЭ WWW.MONTSAME.MN НИЙТЭЛСЭН:2025/07/07     МОНГОЛ УЛС НҮБ-ЫН БҮХ ГИШҮҮН УЛСТАЙ ДИПЛОМАТ ХАРИЛЦАА ТОГТООХ ЗОРИЛТОО БҮРЭН ХЭРЭГЖҮҮЛЛЭЭ WWW.ZINDAA.MN НИЙТЭЛСЭН:2025/07/07     ТЭТГЭВРИЙН ЗЭЭЛИЙН ЗОХИЦУУЛАЛТЫГ ЦУЦЛАВ WWW.NEWS.MN НИЙТЭЛСЭН:2025/07/07    

Johnson & Johnson's one-shot COVID-19 vaccine effective and safe: FDA staff www.reuters.com

(Reuters) - Johnson & Johnson’s one-shot COVID-19 vaccine appeared safe and effective in trials, U.S. Food and Drug Administration (FDA) staff said in documents published on Wednesday, paving the way for its approval for emergency use.
Slideshow ( 2 images )
The FDA’s panel of independent experts meets on Friday to decide whether to approve the shot. While it is not bound to follow the advice of its experts, the FDA usually does and has authorized vaccines from Pfizer and Moderna.
J&J said in documents submitted to the FDA that its data suggested its vaccine was effective at preventing asymptomatic infections. It said that in a preliminary analysis of its trial, it found 16 cases of asymptomatic cases in the placebo group versus two in the vaccine group, or an 88% efficacy rate.
While asymptomatic infection was not the primary goal of the trial, which studied the vaccine’s ability to stop moderate to severe COVID-19, the reduction of asymptomatic cases implies the shot can also cut transmission of the disease.
J&J’s vaccine was 66% effective in preventing COVID-19 against multiple variants in a global trial involving nearly 44,000 people, the company said last month.
Its effectiveness varied from 72% in the United States to 66% in Latin America and 57% in South Africa, where a new variant has spread, though the vaccine was 85% effective overall in stopping severe cases of the disease.
The vaccine was effective in reducing the risk of COVID-19 and preventing PCR-test confirmed COVID-19 at least 14 days after vaccination, the FDA said in its briefing documents.
Fourteen days after injection, only two vaccine recipients developed COVID-19 severe enough to need medical intervention, compared with 14 in the placebo group. After 28 days, no vaccine recipients developed COVID severe enough to require medical intervention whereas seven in the placebo group did.
Three vaccine recipients had severe side effects in the trial that were likely related to the vaccine, but the FDA said its analysis did not raise any specific safety concerns that would preclude issuance of an emergency use authorization.
The FDA said the most common solicited adverse reactions were injection site pain at 48.6%, headache at 39%, fatigue at 38.2% and myalgia at 33.2%. Other side effects included a fever in 9% of participants and a high fever in 0.2% of those who received the vaccine.
The regulator said one case of pericarditis, a heart disease, may have been caused by the vaccine. It said cases of a rare disorder, Guillain-Barre Syndrome, were unlikely to be related to the shot though data was insufficient to determine whether or not the vaccine had caused these side effects.
J&J had not previously released details of its clinical trial data beyond efficacy rates.
Reporting by Manas Mishra in Bengaluru; Mike Erman, Caroline Humer and Rebecca Spalding; Editing by Bernard Orr and David Clarke


Published Date:2021-02-24